Response to "Late relapse rates in patients with early-stage hormone receptor positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy"

J Surg Oncol. 2020 May;121(6):1043. doi: 10.1002/jso.25867. Epub 2020 Feb 17.

Authors

Laura Burkbauer¹, Macy Goldbach¹, Maria Pomponio¹, Julia Tchou^{1

2}

Affiliations

¹ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 32067234
DOI: 10.1002/jso.25867

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Chemotherapy, Adjuvant
Humans
Neoadjuvant Therapy*
Receptor, ErbB-2
Recurrence

Substances

Receptor, ErbB-2